Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Apple Tree leads $50mm Series B round for Syntimmune

Executive Summary

Syntimmune Inc. (developing immune disease therapies targeting the neonatal Fc receptor (FcRn)) raised $50mm through its Series B round. Apple Tree Partners led with a $48mm investment, and was joined by other existing backers. The funds will support development activities including two ongoing Phase Ib/IIa studies with lead monoclonal antibody candidate SYNT001 for pemphigus and warm autoimmune hemolytic anemia.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies